WCBA
PFE icon

Weaver C. Barksdale & Associates’s Pfizer PFE Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,961
Closed -$925K – 65
2024
Q3 		$925K Sell
31,961
-1,691
-5% -$49.3K 0.83% 59
2024
Q2 		$942K Sell
33,652
-802
-2% -$22.1K 0.89% 59
2024
Q1 		$955K Sell
34,454
-404
-1% -$11.2K 0.88% 60
2023
Q4 		$1M Sell
34,858
-11,897
-25% -$360K 0.98% 56
2023
Q3 		$1.55M Buy
46,755
+2,250
+5% +$79.6K 1.32% 47
2023
Q2 		$1.63M Buy
44,505
+8,968
+25% +$349K 1.61% 41
2023
Q1 		$1.45M Sell
35,537
-1,885
-5% -$81.4K 1.36% 49
2022
Q4 		$1.92M Buy
37,422
+1,050
+3% +$50.3K 1.69% 31
2022
Q3 		$1.59M Sell
36,372
-1,445
-4% -$70.2K 1.6% 33
2022
Q2 		$1.98M Buy
37,817
+382
+1% +$19.5K 1.85% 12
2022
Q1 		$1.94M Buy
37,435
+521
+1% +$27K 1.73% 26
2021
Q4 		$2.18M Buy
+36,914
New +$1.83M 1.98% 13
2017
Q4 		$1.52M Sell
44,134
-186
-0.4% -$6.34K 1.59% 28
2017
Q3 		$1.5M Buy
44,320
+648
+1% +$20.8K 1.67% 22
2017
Q2 		$1.39M Hold
43,672
– – 1.62% 27
2017
Q1 		$1.42M Buy
43,672
+11,159
+34% +$352K 1.67% 24
2016
Q4 		$1M Buy
32,513
+3,171
+11% +$96.8K 1.61% 14
2016
Q3 		$943K Buy
29,342
+2,622
+10% +$87.7K 1.58% 24
2016
Q2 		$893K Hold
26,720
– – 1.55% 26
2016
Q1 		$751K Sell
26,720
-79
-0.3% -$2.26K 0.56% 75
2015
Q4 		$821K Hold
26,799
– – 0.64% 56
2015
Q3 		$799K Hold
26,799
– – 0.64% 51
2015
Q2 		$853K Buy
26,799
+747
+3% +$24.3K 0.63% 51
2015
Q1 		$860K Buy
+26,052
New +$828K 0.65% 40

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Weaver C. Barksdale & Associates's PFE Position: Q4 2024 in Review

Weaver C. Barksdale & Associates sold out of Pfizer (PFE) in Q4 2024, closing a stake of 31,961 shares — an estimated $925K sold.

Weaver C. Barksdale & Associates first reported a position in PFE in Q1 2015 and held it in 24 quarters. The position peaked at $2.18M in Q4 2021. 3,001 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

  • Weaver C. Barksdale & Associates reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 31,961 Pfizer shares in Q4 2024, an estimated $925K.
  • Weaver C. Barksdale & Associates first reported a position in Pfizer in Q1 2015 and held it in 24 quarters.
  • Weaver C. Barksdale & Associates's Pfizer position peaked at $2.18M in Q4 2021.
  • 3,001 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Weaver C. Barksdale & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.